Back to Table of contents

Primeur weekly 2017-11-20

Quantum computing

D-Wave announces upgrades to D-Wave 2000Q quantum computer ...

Essential quantum computer component downsized by two orders of magnitude ...

Hardware

University of Oxford acquires Atos' latest supercomputer for Deep Learning programme ...

Toyota Tsusho and D-Wave announce quantum computing collaboration ...

Gidel first to market with application support package for Intel's HLS, offers 5x faster FPGA development ...

Gidel launches new high performance line of acceleration boards based on Intel's Stratix 10 FPGA ...

Argonne to install Comanche system to explore ARM technology for high-performance computing ...

15th Graph500 list reveals top machines for running data applications ...

Applications

Argonne forms new divisions to focus on computation and data science strengths ...

Chinese team employs world's fastest supercomputer to simulate devastating earthquake ...

Physicists mix waves on superconducting qubits ...

Quantum computing with molecules for a quicker search of unsorted databases ...

What is the computational power of the universe? ...

Lawrence Livermore and American Heart Association partner to accelerate drug discovery ...

Supercomputing award of 5.95 billion hours to 55 computational research projects ...

Detailed view of immune proteins could lead to new pathogen-defense strategies ...

The Cloud

Fusion Genomics turns to IBM Cloud to help support advances designed to conquer global pandemics ...

New Oracle Cloud infrastructure innovations deliver unmatched performance and value for the most demanding enterprise, AI and HPC applications ...

Latest version of Red Hat OpenShift Container Platform joins infrastructure and services across hybrid Cloud environments ...

UberCloud and the Stanford Living Heart Project win prestigious Hyperion Innovation Excellence Award ...

Lawrence Livermore and American Heart Association partner to accelerate drug discovery


Supercomputing-based modeling may help validate and accelerate drug research.
15 Nov 2017 Livermore - The American Heart Association (AHA) and Lawrence Livermore National Laboratory (LLNL) have formed a strategic business partnership to overcome the burden of drug discovery, cost and access.

The two organisations will leverage the world’s most powerful supercomputers to accelerate drug discovery. LLNL scientists and engineers in collaboration with AHA-funded scientists will create a simulated environment that rapidly and precisely predicts how drugs bind to their target proteins and will test these predictions in experimental systems to generate a robust drug pipeline of new and targeted therapies.

This collaboration is part of the AHA's newly formed Center for Accelerated Drug Discovery, reinforcing the AHA's commitment to to improve people’s health by accelerating the pace at which drug-protein interactions are identified and documented before actual clinical trials begin.

It takes an average of 10 years for a new medicine to be commercialized in the marketplace and an average cost of $2.6 billion. As the population continues to age, the need for medications to treat chronic conditions, such as heart disease, Alzheimer's disease and diabetes, will continue to increase, challenging the current system to remove barriers to affordable health care and preventive medicine.

LLNL has applied its expertise in computational chemistry to model biological molecules since the early 1990s, and has developed and applied laboratory-based methods to study drug effectiveness and side effects in humans and animals since the 1960s. More recently, LLNL has used computational biology to predict human outcomes for drug safety and efficacy.

In this new partnership, AHA and LLNL aim to develop a unique combination of computational and experimental tools that will allow the biomedical community to validate targeted drug hypotheses that have higher probabilities of success and reduce time to market by potentially 50 percent.

To achieve this goal, LLNS and AHA will collaboratively develop and validate new high-performance computing (HPC) tools to quantitatively predict binding as a guide to on- and off-target molecular interactions.

"Some form of cardiovascular disease affects more than one in every three adult Americans", stated Nancy Brown, CEO of the American Heart Association. "As part of the American Heart Association's Center for Accelerated Drug Discovery, we are committed to taking the guesswork out of drug effectiveness by collaborating with Lawrence Livermore National Laboratory to help patients alleviate not only heart disease, but also suffering for all people everywhere managing other chronic conditions."

"The computing infrastructure at LLNL will enable machine learning and ultimately get safe drugs to the marketplace quicker", stated Felice Lightstone, LLNL's principal investigator on the project. "By bringing world-class, leading-edge engineering and high-impact biological fields together, we can develop a comprehensive reference atlas of cell-protein targets to accelerate and hone drug discovery."

The research and development work under the Cooperative Research and Development Agreement (CRADA) intends to integrate machine learning (ML) approaches to the discovery pipeline to address a critical gap in the ability to predict drug safety and efficacy.

Heart disease is the no. 1 killer worldwide. Stroke ranks second globally and is a leading cause of severe disability. An estimated 17.7 million people die from cardiovascular disease annually, representing 31 percent of all global deaths and of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. AHA is working toward improving the cardiovascular health of all Americans by 20 percent and reducing deaths from cardiovascular diseases and stroke by 20 percent, all by the year 2020. Precision medicine could ultimately reduce the overall cost to the system by developing targeted and affordable medicines for patients.
Source: Lawrence Livermore National Laboratory

Back to Table of contents

Primeur weekly 2017-11-20

Quantum computing

D-Wave announces upgrades to D-Wave 2000Q quantum computer ...

Essential quantum computer component downsized by two orders of magnitude ...

Hardware

University of Oxford acquires Atos' latest supercomputer for Deep Learning programme ...

Toyota Tsusho and D-Wave announce quantum computing collaboration ...

Gidel first to market with application support package for Intel's HLS, offers 5x faster FPGA development ...

Gidel launches new high performance line of acceleration boards based on Intel's Stratix 10 FPGA ...

Argonne to install Comanche system to explore ARM technology for high-performance computing ...

15th Graph500 list reveals top machines for running data applications ...

Applications

Argonne forms new divisions to focus on computation and data science strengths ...

Chinese team employs world's fastest supercomputer to simulate devastating earthquake ...

Physicists mix waves on superconducting qubits ...

Quantum computing with molecules for a quicker search of unsorted databases ...

What is the computational power of the universe? ...

Lawrence Livermore and American Heart Association partner to accelerate drug discovery ...

Supercomputing award of 5.95 billion hours to 55 computational research projects ...

Detailed view of immune proteins could lead to new pathogen-defense strategies ...

The Cloud

Fusion Genomics turns to IBM Cloud to help support advances designed to conquer global pandemics ...

New Oracle Cloud infrastructure innovations deliver unmatched performance and value for the most demanding enterprise, AI and HPC applications ...

Latest version of Red Hat OpenShift Container Platform joins infrastructure and services across hybrid Cloud environments ...

UberCloud and the Stanford Living Heart Project win prestigious Hyperion Innovation Excellence Award ...